Candel Therapeutics
CADL
20 hedge funds and large institutions have $6.77M invested in Candel Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.39% less ownership
Funds ownership: 18.96% → 18.57% (-0.39%)
5% less funds holding
Funds holding: 21 → 20 (-1)
9% less capital invested
Capital invested by funds: $7.44M → $6.77M (-$671K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$175K |
| 2 |
BlackRock
New York
|
+$7.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.49K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$241 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$237K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$64.6K |
| 3 |
E
Ergoteles
New York
|
-$15.6K |
| 4 |
Renaissance Technologies
New York
|
-$12.1K |
| 5 |
BWM
Baystate Wealth Management
Boston,
Massachusetts
|
-$7.85K |
CADL Hedge Fund Activity: Q2 2023 in Review
20 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q2 2023, worth a combined $6.77M — down 9% from $7.44M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CADL and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 3 added.
The largest buyer was Citigroup, opening a new position worth an estimated $175K. The largest seller was Fidelity Investments, cutting an estimated $237K.
- 20 institutional investors held Candel Therapeutics (CADL) as of Q2 2023, down from 21 in Q1 2023.
- Funds reported $6.77M of Candel Therapeutics stock for Q2 2023, down 9% quarter-over-quarter.
- 2 funds opened new Candel Therapeutics positions in Q2 2023 and 3 closed out, a net change of -1 holder.
- The largest Candel Therapeutics buyer in Q2 2023 was Citigroup, an estimated $175K added.
- The largest Candel Therapeutics seller in Q2 2023 was Fidelity Investments, an estimated $237K sold.
Based on aggregated 13F filings for Q2 2023.